JP2021518108A5 - - Google Patents
Info
- Publication number
- JP2021518108A5 JP2021518108A5 JP2020548920A JP2020548920A JP2021518108A5 JP 2021518108 A5 JP2021518108 A5 JP 2021518108A5 JP 2020548920 A JP2020548920 A JP 2020548920A JP 2020548920 A JP2020548920 A JP 2020548920A JP 2021518108 A5 JP2021518108 A5 JP 2021518108A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- cell
- domain
- cells
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023198981A JP7745616B2 (ja) | 2018-03-14 | 2023-11-24 | 腫瘍特異的Ｔ細胞免疫療法用のＩＬ－１３受容体α２（ＩＬ１３Ｒα２）標的キメラ抗原受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643055P | 2018-03-14 | 2018-03-14 | |
| US62/643,055 | 2018-03-14 | ||
| PCT/US2019/021823 WO2019178078A1 (en) | 2018-03-14 | 2019-03-12 | Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023198981A Division JP7745616B2 (ja) | 2018-03-14 | 2023-11-24 | 腫瘍特異的Ｔ細胞免疫療法用のＩＬ－１３受容体α２（ＩＬ１３Ｒα２）標的キメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518108A JP2021518108A (ja) | 2021-08-02 |
| JP2021518108A5 true JP2021518108A5 (enExample) | 2022-03-18 |
| JP7438123B2 JP7438123B2 (ja) | 2024-02-26 |
Family
ID=67908477
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548920A Active JP7438123B2 (ja) | 2018-03-14 | 2019-03-12 | 腫瘍特異的Ｔ細胞免疫療法用のＩＬ－１３受容体α２（ＩＬ１３Ｒα２）標的キメラ抗原受容体 |
| JP2023198981A Active JP7745616B2 (ja) | 2018-03-14 | 2023-11-24 | 腫瘍特異的Ｔ細胞免疫療法用のＩＬ－１３受容体α２（ＩＬ１３Ｒα２）標的キメラ抗原受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023198981A Active JP7745616B2 (ja) | 2018-03-14 | 2023-11-24 | 腫瘍特異的Ｔ細胞免疫療法用のＩＬ－１３受容体α２（ＩＬ１３Ｒα２）標的キメラ抗原受容体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12152079B2 (enExample) |
| EP (1) | EP3765041A4 (enExample) |
| JP (2) | JP7438123B2 (enExample) |
| KR (1) | KR102805003B1 (enExample) |
| CN (1) | CN112236151A (enExample) |
| AU (1) | AU2019234573B2 (enExample) |
| BR (1) | BR112020018670A2 (enExample) |
| CA (1) | CA3093810A1 (enExample) |
| EA (1) | EA202091982A1 (enExample) |
| IL (2) | IL277267B2 (enExample) |
| MX (1) | MX2020009463A (enExample) |
| SG (1) | SG11202008795SA (enExample) |
| WO (1) | WO2019178078A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4491718A3 (en) | 2018-03-14 | 2025-03-26 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
| EP3842461A1 (en) * | 2019-12-23 | 2021-06-30 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors that bind to prostate specific membrane antigen |
| BR112022022953A2 (pt) * | 2020-05-12 | 2023-03-21 | Lyell Immunopharma Inc | Espaçadores de receptores de antígenos quiméricos |
| CN115246883B (zh) * | 2021-02-02 | 2025-04-11 | 浙江理工大学 | 一种抗人源IL13Ra2鲨鱼单域抗体或其抗原结合片段和应用 |
| CA3172530A1 (en) | 2021-02-25 | 2022-09-01 | Spencer PARK | Ror1 targeting chimeric antigen receptor |
| JP2024514101A (ja) * | 2021-04-01 | 2024-03-28 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｉｌ－１３ｒａ２キメラ抗原受容体および使用方法 |
| EP4364746A4 (en) * | 2021-07-01 | 2025-07-23 | Ningbo T Maximum Biopharmaceuticals Co Ltd | UNIVERSAL CAR-T LYMPHOCYTE TARGETING IL13Ra2, ITS PREPARATION METHOD AND ITS APPLICATION |
| CN116589585B (zh) * | 2021-12-29 | 2023-11-24 | 华道(上海)生物医药有限公司 | 一种抗IL13Ra2的纳米抗体及其应用 |
| CN114014941B (zh) * | 2022-01-10 | 2022-04-12 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的嵌合抗原受体及其用途 |
| WO2023138666A1 (en) * | 2022-01-19 | 2023-07-27 | Utc Therapeutics (Shanghai) Co., Ltd. | Circular rna and use thereof |
| CN114990069B (zh) * | 2022-05-17 | 2023-09-22 | 郑州大学第一附属医院 | 一种过表达slc43a2的嵌合抗原受体t细胞的制备方法和应用 |
| CN114805581B (zh) * | 2022-06-29 | 2022-10-14 | 上海优替济生生物医药有限公司 | 靶向il13ra2的抗体、嵌合抗原受体及其用途 |
| WO2024041650A1 (en) * | 2022-08-25 | 2024-02-29 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof |
| CN115960257B (zh) * | 2022-09-29 | 2023-10-27 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的经优化的嵌合抗原受体及其用途 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025154925A1 (ko) * | 2024-01-18 | 2025-07-24 | 엑셀라몰(주) | IL13Ra2에 결합하는 폴리펩타이드 약물 접합체 및 이의 용도 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| US8822647B2 (en) | 2008-08-26 | 2014-09-02 | City Of Hope | Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells |
| ES2717629T3 (es) | 2009-11-03 | 2019-06-24 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas |
| PL3824905T3 (pl) | 2012-08-20 | 2025-05-05 | Fred Hutchinson Cancer Center | Sposób i kompozycje do immunoterapii komórkowej |
| HK1214161A1 (zh) | 2012-11-07 | 2016-07-22 | 辉瑞公司 | 抗IL-13受体α2抗体和抗体-药物缀合物 |
| CA2893359C (en) | 2012-12-05 | 2021-12-28 | Strategia Therapeutics, Inc. | Protein expression enhancing polypeptides |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| EP3974520A1 (en) | 2013-05-14 | 2022-03-30 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| TWI805109B (zh) * | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| EP3587446A1 (en) | 2014-09-19 | 2020-01-01 | City of Hope | Costimulatory chimeric antigen receptor t cells targeting il13 r alpha 2 |
| JP7264592B2 (ja) * | 2015-01-26 | 2023-04-25 | ザ ユニバーシティー オブ シカゴ | ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用 |
| AU2016297605A1 (en) | 2015-07-21 | 2018-02-15 | City Of Hope | T cells for expression of chimeric antigen receptors and other receptors |
| CN116334205A (zh) | 2015-09-03 | 2023-06-27 | 诺华股份有限公司 | 预测细胞因子释放综合征的生物标志物 |
| BR112018015836A2 (en) | 2016-02-05 | 2018-12-26 | City Of Hope | engineered t-cell administration for central nervous system cancer treatment |
| WO2017172981A2 (en) | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| KR20190015520A (ko) * | 2016-06-07 | 2019-02-13 | 마크로제닉스, 인크. | 조합 치료법 |
| CA3031955A1 (en) | 2016-07-29 | 2018-02-01 | Juno Therapeutics, Inc. | Immunomodulatory polypeptides and related compositions and methods |
| US12083148B2 (en) * | 2017-02-22 | 2024-09-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | IL13Ra2-binding chimeric antigen receptors |
| EP4491718A3 (en) | 2018-03-14 | 2025-03-26 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
-
2019
- 2019-03-12 BR BR112020018670-8A patent/BR112020018670A2/pt unknown
- 2019-03-12 CA CA3093810A patent/CA3093810A1/en active Pending
- 2019-03-12 SG SG11202008795SA patent/SG11202008795SA/en unknown
- 2019-03-12 IL IL277267A patent/IL277267B2/en unknown
- 2019-03-12 US US16/979,471 patent/US12152079B2/en active Active
- 2019-03-12 JP JP2020548920A patent/JP7438123B2/ja active Active
- 2019-03-12 AU AU2019234573A patent/AU2019234573B2/en active Active
- 2019-03-12 IL IL314877A patent/IL314877B2/en unknown
- 2019-03-12 EA EA202091982A patent/EA202091982A1/ru unknown
- 2019-03-12 WO PCT/US2019/021823 patent/WO2019178078A1/en not_active Ceased
- 2019-03-12 CN CN201980031550.0A patent/CN112236151A/zh active Pending
- 2019-03-12 EP EP19768040.8A patent/EP3765041A4/en active Pending
- 2019-03-12 MX MX2020009463A patent/MX2020009463A/es unknown
- 2019-03-12 KR KR1020207028966A patent/KR102805003B1/ko active Active
-
2023
- 2023-11-24 JP JP2023198981A patent/JP7745616B2/ja active Active
-
2024
- 2024-10-16 US US18/917,176 patent/US20250043013A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102805003B1 (ko) | 종양 특이적 t 세포 면역요법을 위한 il-13 수용체 알파 2 (il13ra2) 키메라 항원 수용체 | |
| US10457731B2 (en) | Multipartite signaling proteins and uses thereof | |
| JP7082574B2 (ja) | 免疫療法用改変細胞 | |
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP5851419B2 (ja) | ヘテロダイマー結合タンパク質およびその使用 | |
| WO2022089353A1 (zh) | 靶向bcma的单域抗体及其用途 | |
| JP2019525771A5 (enExample) | ||
| JP2018512153A5 (enExample) | ||
| US20130129723A1 (en) | Heterodimer Binding Proteins and Uses Thereof | |
| CN114085855A (zh) | 通用嵌合抗原受体表达性免疫细胞及其制造方法和治疗用途 | |
| JP2022542559A5 (enExample) | ||
| US20230235064A1 (en) | Bispecific immune cell engagers with binding specificity for hla-g and another antigen | |
| CN113039206A (zh) | 包含b7h3嵌合抗原受体的方法和组合物 | |
| JP2021523949A5 (enExample) | ||
| JP2024512382A (ja) | Ｐｄ－１標的化ｉｌ－２バリアント免疫コンジュゲートと抗ｔｙｒｐ１／抗ｃｄ３二重特異性抗体の併用療法 | |
| CA3234046A1 (en) | Anti-bcma single domain antibodies and therapeutic constructs | |
| TW202444751A (zh) | 重組Ｆｃ域—ＩＬ２變異體多肽及與膜錨定抗原結合多肽的組合療法 | |
| JP2021518111A5 (enExample) | ||
| RU2809160C2 (ru) | Виды комбинированной терапии с использованием химерных антигенных рецепторов и ингибиторов pd-1 |